Patent intelligence · US
US 7105643
Monoclonal antibodies specific for crack cocaine metabolites, a cell line producing the same, and crack cocaine conjugates
Monoclonal antibodies specific for crack cocaine metabolites, a cell line producing the same, and crack cocaine conjugates
Patent details — US 7105643
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 12, 2006
- Expiration
- Sep 7, 2026
- Applicant
- The United States of America as represented by the Attorney General of the Dept. of Justice
- Claims
- 16
- CPC classes
- A61K, A61K2039/6081, A61K39/0013
Quick answer
US 7105643 (Monoclonal antibodies specific for crack cocaine metabolites, a cell line producing the same, and crack cocaine conjugates) is held by The United States of America as represented by the Attorney General of the Dept. of Justice. Status: granted. Granted Sep 12, 2006. Expires Sep 7, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The United States of America as represented by the Attorney General of the Dept. of Justice
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/6081, A61K39/0013
More from The United States of America as represented by the Attorney General of the Dept. of Justice
Related pharmaceutical patents in our USPTO index.
-
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
granted -
US 12419941
Poultry drinking water-based vaccine delivery system and method
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12404317
T cell receptors recognizing MHC class II-restricted MAGE-A3
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted
Frequently asked questions
What is US patent 7105643?
US 7105643 (Monoclonal antibodies specific for crack cocaine metabolites, a cell line producing the same, and crack cocaine conjugates) is held by The United States of America as represented by the Attorney General of the Dept. of Justice. Status: granted. Granted Sep 12, 2006. Expires Sep 7, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7105643?
The United States of America as represented by the Attorney General of the Dept. of Justice is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.
When does US 7105643 expire?
Our index shows an expiration date of Sep 7, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.